洛司普托 TQ0032
面议
- TargetMol
- 生产商
- 进口
- 美国
- 现货
- 全国
- 6
- 0
Product IntroductionBioactivity英文名: Rosiptor描述: Rosiptor (AQX-1125) 是一种选择性，具有口服活性的磷酸酶 SHIP1激活剂。它在体外抑制 Akt 磷酸化、炎症介质生成和白细胞趋
AI问答
配套的仪器设备？
可以搭配的相关耗材试剂？
耗材描述
Product Introduction
Bioactivity
英文名: Rosiptor
描述: Rosiptor (AQX-1125) 是一种选择性，具有口服活性的磷酸酶 SHIP1激活剂。它在体外抑制 Akt 磷酸化、炎症介质生成和白细胞趋化，具有抗炎作用。
细胞实验: Cell Line: MOLT-4 cells and SHIP1-deficient Jurkat cells (IGF-1 stimulation) [1]. Concentration: 0.1, 1, 10 μM. Incubation Time: 30 minutes
动物实验: Animal Model: 6-8 weeks old male CD-1 mice[1]. Dosage: 3, 10, 30 mg/kg. Administration: p.o., daily for 3 days
体外活性: In MOLT-4 but not Jurkat cells, Rosiptor (0.1-10 μM, 30 minutes) inhibits Akt activation [1].
体内活性: Rosiptor (10 mg/kg, p.o.) has the Cmax value of 0.830 μM and the t1/2 value of 5.2 hours. AQX-1125 also exhibits >80% oral bioavailability [1]. Rosiptor (3-30 mg/kg, p.o., daily for 3 days) significantly reduces the total number of BAL leukocytes in NSC-125066-challenged mice and reduces MPO activity [2].
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: DMSO : 145 mg/mL (451 mM)
关键字: AQX1125 | Phosphatase | Rosiptor | Inhibitor | AQX 1125 | inhibit
相关产品: EWP 815 | PP5-IN-1 | Osunprotafib | Abyssinone V | Tacrolimus monohydrate | CDC25B-IN-1 | (R)-Azasetron besylate | ZLDI-8 | Sal003 | 3α-Aminocholestane
相关库: Glycometabolism Compound Library | ReFRAME Related Library | Anti-Metabolism Disease Compound Library | Phosphatase Inhibitor Library | Metabolism Compound Library | Orally Active Compound Library | NO PAINS Compound Library
Bioactivity
英文名: Rosiptor
描述: Rosiptor (AQX-1125) 是一种选择性，具有口服活性的磷酸酶 SHIP1激活剂。它在体外抑制 Akt 磷酸化、炎症介质生成和白细胞趋化，具有抗炎作用。
细胞实验: Cell Line: MOLT-4 cells and SHIP1-deficient Jurkat cells (IGF-1 stimulation) [1]. Concentration: 0.1, 1, 10 μM. Incubation Time: 30 minutes
动物实验: Animal Model: 6-8 weeks old male CD-1 mice[1]. Dosage: 3, 10, 30 mg/kg. Administration: p.o., daily for 3 days
体外活性: In MOLT-4 but not Jurkat cells, Rosiptor (0.1-10 μM, 30 minutes) inhibits Akt activation [1].
体内活性: Rosiptor (10 mg/kg, p.o.) has the Cmax value of 0.830 μM and the t1/2 value of 5.2 hours. AQX-1125 also exhibits >80% oral bioavailability [1]. Rosiptor (3-30 mg/kg, p.o., daily for 3 days) significantly reduces the total number of BAL leukocytes in NSC-125066-challenged mice and reduces MPO activity [2].
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: DMSO : 145 mg/mL (451 mM)
关键字: AQX1125 | Phosphatase | Rosiptor | Inhibitor | AQX 1125 | inhibit
相关产品: EWP 815 | PP5-IN-1 | Osunprotafib | Abyssinone V | Tacrolimus monohydrate | CDC25B-IN-1 | (R)-Azasetron besylate | ZLDI-8 | Sal003 | 3α-Aminocholestane
相关库: Glycometabolism Compound Library | ReFRAME Related Library | Anti-Metabolism Disease Compound Library | Phosphatase Inhibitor Library | Metabolism Compound Library | Orally Active Compound Library | NO PAINS Compound Library
猜你喜欢
感兴趣产品